TN2009000145A1 - Compositions and methods for modulating c-kit and pdgfr receptors - Google Patents
Compositions and methods for modulating c-kit and pdgfr receptorsInfo
- Publication number
- TN2009000145A1 TN2009000145A1 TNP2009000145A TN2009000145A TN2009000145A1 TN 2009000145 A1 TN2009000145 A1 TN 2009000145A1 TN P2009000145 A TNP2009000145 A TN P2009000145A TN 2009000145 A TN2009000145 A TN 2009000145A TN 2009000145 A1 TN2009000145 A1 TN 2009000145A1
- Authority
- TN
- Tunisia
- Prior art keywords
- methods
- raf
- kit
- pdgfr
- compounds
- Prior art date
Links
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 title abstract 2
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 title abstract 2
- 101150093908 PDGFRB gene Proteins 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 102000005962 receptors Human genes 0.000 title 1
- 108020003175 receptors Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- -1 CSFlR Proteins 0.000 abstract 2
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 abstract 2
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 abstract 2
- 230000002159 abnormal effect Effects 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 abstract 1
- 102100023274 Dual specificity mitogen-activated protein kinase kinase 4 Human genes 0.000 abstract 1
- 102100023401 Dual specificity mitogen-activated protein kinase kinase 6 Human genes 0.000 abstract 1
- 101100127166 Escherichia coli (strain K12) kefB gene Proteins 0.000 abstract 1
- 101150036586 FES gene Proteins 0.000 abstract 1
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 abstract 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 abstract 1
- 101001115395 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 4 Proteins 0.000 abstract 1
- 101000624426 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 6 Proteins 0.000 abstract 1
- 101100457333 Homo sapiens MAPK11 gene Proteins 0.000 abstract 1
- 101000950695 Homo sapiens Mitogen-activated protein kinase 8 Proteins 0.000 abstract 1
- 101000950669 Homo sapiens Mitogen-activated protein kinase 9 Proteins 0.000 abstract 1
- 101000606502 Homo sapiens Protein-tyrosine kinase 6 Proteins 0.000 abstract 1
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 abstract 1
- 101000922131 Homo sapiens Tyrosine-protein kinase CSK Proteins 0.000 abstract 1
- 101150028321 Lck gene Proteins 0.000 abstract 1
- 108700036166 Mitogen-Activated Protein Kinase 11 Proteins 0.000 abstract 1
- 102100026929 Mitogen-activated protein kinase 11 Human genes 0.000 abstract 1
- 102100037808 Mitogen-activated protein kinase 8 Human genes 0.000 abstract 1
- 102100037809 Mitogen-activated protein kinase 9 Human genes 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 102100039810 Protein-tyrosine kinase 6 Human genes 0.000 abstract 1
- 108010029869 Proto-Oncogene Proteins c-raf Proteins 0.000 abstract 1
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 abstract 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 abstract 1
- 101150046814 SAPK2 gene Proteins 0.000 abstract 1
- 108060006706 SRC Proteins 0.000 abstract 1
- 101001045447 Synechocystis sp. (strain PCC 6803 / Kazusa) Sensor histidine kinase Hik2 Proteins 0.000 abstract 1
- 108010009583 Transforming Growth Factors Proteins 0.000 abstract 1
- 102100031167 Tyrosine-protein kinase CSK Human genes 0.000 abstract 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 abstract 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 abstract 1
- 230000002074 deregulated effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 abstract 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 abstract 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 abstract 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 239000003909 protein kinase inhibitor Substances 0.000 abstract 1
- 102000009929 raf Kinases Human genes 0.000 abstract 1
- 108010077182 raf Kinases Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Addiction (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86243006P | 2006-10-20 | 2006-10-20 | |
| PCT/US2007/081538 WO2008051757A1 (fr) | 2006-10-20 | 2007-10-16 | Compositions et procédés de modulation de récepteurs de c-kit et de facteur de croissance dérivé de plaquettes (pdgfr) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2009000145A1 true TN2009000145A1 (en) | 2010-10-18 |
Family
ID=39027274
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP2009000145A TN2009000145A1 (en) | 2006-10-20 | 2009-04-17 | Compositions and methods for modulating c-kit and pdgfr receptors |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US7678792B2 (fr) |
| EP (1) | EP2076513A1 (fr) |
| JP (1) | JP2010506948A (fr) |
| KR (1) | KR101079520B1 (fr) |
| CN (1) | CN101528744A (fr) |
| AR (1) | AR063343A1 (fr) |
| AU (1) | AU2007309279B2 (fr) |
| BR (1) | BRPI0718162A2 (fr) |
| CA (1) | CA2667010A1 (fr) |
| CL (1) | CL2007003005A1 (fr) |
| CO (1) | CO6170361A2 (fr) |
| CR (1) | CR10717A (fr) |
| EA (1) | EA200900573A1 (fr) |
| EC (1) | ECSP099353A (fr) |
| IL (1) | IL197875A0 (fr) |
| MA (1) | MA30888B1 (fr) |
| MX (1) | MX2009004141A (fr) |
| NI (1) | NI200900061A (fr) |
| NO (1) | NO20091949L (fr) |
| PE (1) | PE20081262A1 (fr) |
| SM (1) | SMP200900027B (fr) |
| TN (1) | TN2009000145A1 (fr) |
| TW (1) | TW200825081A (fr) |
| WO (1) | WO2008051757A1 (fr) |
| ZA (1) | ZA200902711B (fr) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003078448A1 (fr) | 2002-03-13 | 2003-09-25 | Signum Biosciences, Inc. | Modulation de la methylation de proteines et du phosphate des phosphoproteines |
| EP1843734A4 (fr) | 2005-02-03 | 2008-09-10 | Signum Biosciences Inc | Compositions et procedes pour l'amelioration de la fonction cognitive |
| US7923041B2 (en) | 2005-02-03 | 2011-04-12 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
| US7897762B2 (en) | 2006-09-14 | 2011-03-01 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of proliferative diseases |
| US8188113B2 (en) * | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| ZA200902587B (en) | 2006-11-09 | 2010-06-30 | Alcon Res Ltd | Water insoluble polymer matrix for drug delivery |
| TWI498115B (zh) * | 2007-12-27 | 2015-09-01 | Daiichi Sankyo Co Ltd | 咪唑羰基化合物 |
| ATE551342T1 (de) | 2008-02-22 | 2012-04-15 | Irm Llc | Heterocyclische verbindungen und zusammensetzungen als c-kit- und pdgfr- kinasehemmer |
| CA2758424C (fr) | 2008-04-21 | 2018-03-06 | Signum Biosciences, Inc. | Derives de tryptamine comme modulateurs de la methylation de pp2a |
| FR2930552B1 (fr) * | 2008-04-24 | 2012-10-12 | Centre Nat Rech Scient | N-acylthiourees et n-acylurees inhibiteurs de la voie de signalisation des proteines hedgehog |
| EA201001847A1 (ru) * | 2008-06-11 | 2011-08-30 | Айрм Ллк | Соединения и композиции, применяемые для лечения малярии |
| CA2733010A1 (fr) * | 2008-08-05 | 2010-02-11 | George Mason Intellectual Properties, Inc. | Alterations de voie de signalisation et elevations de medicament cible dans le cancer colorectal metastasique metachrone primaire compare a une maladie non metastasique |
| KR20110099687A (ko) * | 2008-10-29 | 2011-09-08 | 데시페라 파마슈티칼스, 엘엘씨. | 항-암과 항-증식성 활성을 나타내는 시클로프로판 아미드와 유사체 |
| TW201034675A (en) * | 2008-12-18 | 2010-10-01 | Sanofi Aventis | Method for treating macular degeneration |
| US8674095B2 (en) | 2008-12-19 | 2014-03-18 | Afraxis Holdings, Inc. | Compounds for treating neuropsychiatric conditions |
| WO2010092041A1 (fr) * | 2009-02-13 | 2010-08-19 | Fovea Pharmaceuticals Sa | [1, 2, 4] triazolo [1, 5 -a] pyridines servant d'inhibiteurs de kinases |
| MX2012004157A (es) | 2009-10-09 | 2012-08-03 | Afraxis Inc | 8-etil-6-(aril)pirido[2.3-d]pirimidin-7(8h)-onas para el tratamiento de trastornos del snc. |
| EA201201052A1 (ru) | 2010-01-29 | 2013-02-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Замещенные нафтиридины и их применение в качестве ингибиторов киназы syk |
| JP5728499B2 (ja) * | 2010-02-05 | 2015-06-03 | アイアールエム・リミテッド・ライアビリティ・カンパニーＩｒｍ，Ｌｌｃ | タンパク質キナーゼ阻害剤としての化合物および組成物 |
| US20120189633A1 (en) * | 2011-01-26 | 2012-07-26 | Kolltan Pharmaceuticals, Inc. | Anti-kit antibodies and uses thereof |
| WO2012148994A1 (fr) | 2011-04-25 | 2012-11-01 | Usher Iii Initiative | Pyrazolopyridazines et méthodes de traitement des maladies dégénératives de la rétine et la perte d'audition associée au syndrome de usher |
| JP5860960B2 (ja) | 2011-07-26 | 2016-02-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換キノリン類及び医薬としてのそれらの使用 |
| AP2014007595A0 (en) * | 2011-09-30 | 2014-04-30 | Kineta Inc | Anti-viral compounds |
| KR102190848B1 (ko) | 2012-05-15 | 2020-12-15 | 노파르티스 아게 | Abl1, abl2 및 bcr-abl1의 활성을 억제하기 위한 화합물 및 조성물 |
| TR201807023T4 (tr) | 2012-05-15 | 2018-06-21 | Novartis Ag | Abl1, abl2 ve bcr- abl1 aktivitesinin inhibe edilmesi için benzamid türevleri. |
| EP2861576B1 (fr) | 2012-05-15 | 2018-01-10 | Novartis AG | Dérivés de benzamide pour inhiber l'activité d'abl1, d'abl2 et de bcr-abl2 |
| EP2858988B1 (fr) | 2012-05-15 | 2018-02-28 | Novartis AG | Dérivés de benzamide pour inhiber l'activité d'abl1, d'abl2 et de bcr-abl2 |
| US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| KR101652229B1 (ko) * | 2012-06-07 | 2016-08-30 | 데시페라 파마슈티칼스, 엘엘씨. | 증식성 질환의 치료를 위한 키나제 저해제로서 유용한 다이하이드로나프타이리딘 및 관련 화합물 |
| NZ630363A (en) | 2012-07-25 | 2018-09-28 | Celldex Therapeutics Inc | Anti-kit antibodies and uses thereof |
| US9227976B2 (en) | 2012-10-25 | 2016-01-05 | Usher Iii Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
| MX2015017532A (es) * | 2013-06-26 | 2016-10-26 | Proteostasis Therapeutics Inc | Métodos para modular la actividad del regulador de transmembrana de fibrosis quística. |
| GB201401886D0 (en) | 2014-02-04 | 2014-03-19 | Lytix Biopharma As | Neurodegenerative therapies |
| CA2942387A1 (fr) | 2014-03-13 | 2015-09-17 | Proteostasis Therapeutics, Inc. | Composes, compositions et procedes pour augmenter l'activite cftr |
| CA2942386A1 (fr) | 2014-03-13 | 2015-09-17 | Proteostasis Therapeutics, Inc. | Composes, compositions et procedes pour augmenter l'activite du cftr |
| EP3145543A4 (fr) | 2014-05-23 | 2017-12-13 | Celldex Therapeutics, Inc. | Traitement des affections associées aux éosinophiles ou aux mastocytes |
| WO2015196071A1 (fr) | 2014-06-19 | 2015-12-23 | Proteostasis Therapeutics, Inc. | Composés, compositions et procédés pour augmenter l'activité du cftr |
| CN105085489B (zh) | 2014-11-05 | 2019-03-01 | 益方生物科技（上海）有限公司 | 嘧啶或吡啶类化合物、其制备方法和医药用途 |
| US10392378B2 (en) | 2014-12-23 | 2019-08-27 | Proteostasis Therapeutics, Inc. | Derivatives of 5-phenyl- or 5-heteroarylathiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis |
| MA41253A (fr) | 2014-12-23 | 2017-10-31 | Proteostasis Therapeutics Inc | Composés, compositions et procédés pour augmenter l'activité du cftr |
| US10738011B2 (en) | 2014-12-23 | 2020-08-11 | Proteostasis Therapeutics, Inc. | Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis |
| CA2971835A1 (fr) | 2014-12-23 | 2016-06-30 | Proteostasis Therapeutics, Inc. | Derives de 3-heteroarylisoxazol-5-amide carboxylique utiles dans le traitement, entre autres, d'une fibrose kystique |
| WO2017019589A1 (fr) | 2015-07-24 | 2017-02-02 | Proteostasis Therapeutics, Inc. | Composés, compositions et procédés pour augmenter l'activité du cftr |
| CN105664178B (zh) * | 2015-09-24 | 2019-08-20 | 洪健 | Syk作为肝纤维化/硬化治疗靶点的应用 |
| SG11201802798WA (en) | 2015-10-06 | 2018-05-30 | Proteostasis Therapeutics Inc | Compounds, compositions, and methods for modulating cftr |
| CN107286077B (zh) * | 2016-04-01 | 2021-04-02 | 合肥中科普瑞昇生物医药科技有限公司 | 一种选择性的c-kit激酶抑制剂 |
| US10662207B2 (en) | 2016-04-07 | 2020-05-26 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for modulating CFTR |
| ES2954658T3 (es) | 2016-06-21 | 2023-11-23 | Proteostasis Therapeutics Inc | Compuestos, composiciones y procedimientos para aumentar la actividad de CFTR |
| AU2017355603A1 (en) * | 2016-11-04 | 2019-06-20 | Auckland Uniservices Limited | Tricyclic heterocyclic derivatives and uses thereof |
| MA49014A (fr) | 2017-03-21 | 2020-02-05 | Arbutus Biopharma Corp | Dihydroindène-4-carboxamides substitués, leurs analogues et procédés d'utilisation correspondant |
| AU2018266911C1 (en) | 2017-05-12 | 2022-10-20 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| CA3065365C (fr) * | 2017-05-30 | 2025-09-16 | Deciphera Pharmaceuticals, Llc | Utilisation de 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridine-3-yl]-2-fluorophenyl]-3-phenyluree et de ses analogues pour le traitement de cancers associes a des anomalies genetiques au niveau du recepteur alpha du facteur de croissance derive des plaquettes |
| CN111094286B (zh) * | 2017-09-20 | 2022-07-29 | 浙江海正药业股份有限公司 | 1,2-二氢-1,6-萘啶类衍生物、其制备方法及其在医药上的用途 |
| PT3684767T (pt) | 2017-09-22 | 2024-07-29 | Jubilant Epipad LLC | Compostos heterocíclicos como inibidores de pad |
| CA3076476A1 (fr) | 2017-10-18 | 2019-04-25 | Jubilant Epipad LLC | Composes imidazo-pyridine a utiliser en tant qu'inhibiteurs de pad |
| US11629135B2 (en) | 2017-11-06 | 2023-04-18 | Jubilant Prodell Llc | Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation |
| AU2018372211B2 (en) | 2017-11-24 | 2023-02-02 | Jubilant Episcribe LLC, | Heterocyclic compounds as PRMT5 inhibitors |
| KR102708050B1 (ko) | 2018-01-31 | 2024-09-24 | 데시페라 파마슈티칼스, 엘엘씨. | 비만 세포증의 치료를 위한 병용 요법 |
| SG11202007198WA (en) | 2018-01-31 | 2020-08-28 | Deciphera Pharmaceuticals Llc | Combination therapy for the treatment of gastrointestinal stromal tumors |
| JP7279063B6 (ja) | 2018-03-13 | 2024-02-15 | ジュビラント プローデル エルエルシー | Ｐｄ１／ｐｄ－ｌ１相互作用／活性化の阻害剤としての二環式化合物 |
| WO2019213244A1 (fr) | 2018-05-02 | 2019-11-07 | Enanta Pharmaceuticals, Inc. | Inhibiteurs de la kinase 1 régulant le signal d'apoptose contenant des tétrazoles et leurs méthodes d'utilisation |
| WO2020041417A1 (fr) * | 2018-08-22 | 2020-02-27 | Enanta Pharmaceuticals, Inc. | Inhibiteurs de la kinase 1 régulant le signal d'apoptose contenant un cycloalkyle et leurs procédés d'utilisation |
| CA3103335C (fr) | 2018-09-14 | 2023-10-03 | Abbisko Therapeutics Co., Ltd. | Inhibiteur de fgfr, son procede de preparation et son application |
| US11345699B2 (en) | 2018-11-19 | 2022-05-31 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| UA128431C2 (uk) | 2018-11-26 | 2024-07-10 | Форті Севен, Інк. | ГУМАНІЗОВАНЕ АНТИТІЛО ДО c-Kit |
| EP3938363A1 (fr) | 2019-03-11 | 2022-01-19 | Teva Pharmaceuticals International GmbH | Formes à l'état solide de riprétinib |
| WO2020198214A1 (fr) | 2019-03-25 | 2020-10-01 | Enanta Pharmaceuticals, Inc. | Inhibiteurs de la kinase 1 régulant le signal d'apoptose et leurs procédés d'utilisation |
| WO2021030405A1 (fr) | 2019-08-12 | 2021-02-18 | Deciphera Pharmaceuticals, Llc | Ripretinib pour le traitement de tumeurs stromales gastro-intestinales |
| CN114615982A (zh) | 2019-08-12 | 2022-06-10 | 德西费拉制药有限责任公司 | 用于治疗胃肠道间质瘤的瑞普替尼 |
| WO2021039791A1 (fr) * | 2019-08-25 | 2021-03-04 | 国立大学法人山口大学 | Composition médicinale pour la prévention ou le traitement de maladies associées à l'angiogenèse |
| MX2022008103A (es) | 2019-12-30 | 2022-09-19 | Deciphera Pharmaceuticals Llc | Formulaciones de inhibidores de la cinasa amorfa y metodos de estas. |
| CN118948772A (zh) | 2019-12-30 | 2024-11-15 | 德西费拉制药有限责任公司 | 1-(4溴-5-(1乙基-7-(甲氨基)-2侧氧基-1,2-二氢-1,6-萘啶-3基)-2氟苯基)-3-苯基脲的组合物 |
| US20210315869A1 (en) * | 2020-04-02 | 2021-10-14 | Plexxikon Inc. | Compounds and methods for csk modulation and indications therefor |
| AU2021381949A1 (en) | 2020-11-18 | 2023-06-15 | Deciphera Pharmaceuticals, Llc | Gcn2 and perk kinase inhibitors and methods of use thereof |
| CN115108997A (zh) * | 2021-03-22 | 2022-09-27 | 南开大学 | 一类具抑菌活性的磺酰脲类化合物的合成与应用 |
| WO2023050007A1 (fr) * | 2021-09-29 | 2023-04-06 | Repare Therapeutics Inc. | Composés n-([(l,3,4-thiadiazolyle) ou (thiazolyle)]-5-substitués)carboxamide (substitué) et leur utilisation pour inhiber la polymérase thêta humaine |
| TW202342055A (zh) | 2022-02-03 | 2023-11-01 | 美商奇奈特生物製藥公司 | Raf激酶抑制劑 |
| EP4572758A1 (fr) * | 2022-08-19 | 2025-06-25 | Purdue Research Foundation | Inhibiteurs des interactions protéine-protéine |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
| AU2023352129A1 (en) * | 2022-09-29 | 2025-05-01 | Repare Therapeutics Inc. | N-(5-substituted-[(1,3,4-thiadiazolyl) or (1,3-thiazolyl)](substituted)carboxamide compounds, pharmaceutical compositions, and methods of preparing the amide compounds and of their use |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001292320A1 (en) | 2000-10-02 | 2002-04-15 | Tanabe Seiyaku Co., Ltd. | Benzylamine compound, process for producing the same, and intermediate therefor |
| BRPI0415210A (pt) * | 2003-10-08 | 2006-12-05 | Irm Llc | compostos e composições como inibidores de proteìna cinase |
| CA2592116A1 (fr) * | 2004-12-23 | 2006-08-03 | Deciphera Pharmaceuticals, Llc | Medicaments anti-inflammatoires |
| WO2006071940A2 (fr) | 2004-12-23 | 2006-07-06 | Deciphera Pharmaceuticals, Llc | Modulateurs d'enzymes et traitements |
| KR20080109095A (ko) * | 2006-05-15 | 2008-12-16 | 아이알엠 엘엘씨 | Ｆｇｆ 수용체 키나제 억제제를 위한 조성물 및 방법 |
| US8188113B2 (en) * | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| CA2667487C (fr) * | 2006-11-06 | 2017-04-04 | Supergen, Inc. | Derives d'imidazo[1,2-b]pyridazine et de pyrazolo[1,5-a]pyrimidine et utilisation de ceux-ci comme inhibiteurs de proteines kinases |
-
2007
- 2007-10-16 KR KR1020097008062A patent/KR101079520B1/ko not_active Expired - Fee Related
- 2007-10-16 BR BRPI0718162-0A patent/BRPI0718162A2/pt not_active IP Right Cessation
- 2007-10-16 CA CA002667010A patent/CA2667010A1/fr not_active Abandoned
- 2007-10-16 CN CNA2007800390373A patent/CN101528744A/zh active Pending
- 2007-10-16 WO PCT/US2007/081538 patent/WO2008051757A1/fr not_active Ceased
- 2007-10-16 JP JP2009533484A patent/JP2010506948A/ja active Pending
- 2007-10-16 MX MX2009004141A patent/MX2009004141A/es active IP Right Grant
- 2007-10-16 AU AU2007309279A patent/AU2007309279B2/en not_active Ceased
- 2007-10-16 EP EP07844322A patent/EP2076513A1/fr not_active Ceased
- 2007-10-16 US US11/873,196 patent/US7678792B2/en not_active Expired - Fee Related
- 2007-10-16 EA EA200900573A patent/EA200900573A1/ru unknown
- 2007-10-19 CL CL200703005A patent/CL2007003005A1/es unknown
- 2007-10-19 AR ARP070104639A patent/AR063343A1/es unknown
- 2007-10-19 PE PE2007001422A patent/PE20081262A1/es not_active Application Discontinuation
- 2007-10-19 TW TW096139384A patent/TW200825081A/zh unknown
-
2009
- 2009-03-26 IL IL197875A patent/IL197875A0/en unknown
- 2009-04-16 CR CR10717A patent/CR10717A/es not_active Application Discontinuation
- 2009-04-17 CO CO09039151A patent/CO6170361A2/es not_active Application Discontinuation
- 2009-04-17 TN TNP2009000145A patent/TN2009000145A1/fr unknown
- 2009-04-20 SM SM200900027T patent/SMP200900027B/it unknown
- 2009-04-20 ZA ZA200902711A patent/ZA200902711B/xx unknown
- 2009-04-20 NI NI200900061A patent/NI200900061A/es unknown
- 2009-05-13 MA MA31869A patent/MA30888B1/fr unknown
- 2009-05-19 NO NO20091949A patent/NO20091949L/no not_active Application Discontinuation
- 2009-05-20 EC EC2009009353A patent/ECSP099353A/es unknown
- 2009-12-02 US US12/629,665 patent/US8106068B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| PE20081262A1 (es) | 2008-10-29 |
| MX2009004141A (es) | 2009-05-01 |
| SMP200900027B (it) | 2010-01-19 |
| BRPI0718162A2 (pt) | 2013-11-26 |
| TW200825081A (en) | 2008-06-16 |
| ZA200902711B (en) | 2010-05-26 |
| US7678792B2 (en) | 2010-03-16 |
| AU2007309279A1 (en) | 2008-05-02 |
| CR10717A (es) | 2009-07-02 |
| WO2008051757A1 (fr) | 2008-05-02 |
| NI200900061A (es) | 2010-03-10 |
| NO20091949L (no) | 2009-05-19 |
| AU2007309279B2 (en) | 2011-03-24 |
| SMAP200900027A (it) | 2009-07-14 |
| JP2010506948A (ja) | 2010-03-04 |
| CA2667010A1 (fr) | 2008-05-02 |
| KR101079520B1 (ko) | 2011-11-03 |
| ECSP099353A (es) | 2009-06-30 |
| CO6170361A2 (es) | 2010-06-18 |
| US20100081656A1 (en) | 2010-04-01 |
| AR063343A1 (es) | 2009-01-21 |
| US8106068B2 (en) | 2012-01-31 |
| IL197875A0 (en) | 2009-12-24 |
| KR20090054477A (ko) | 2009-05-29 |
| US20080176846A1 (en) | 2008-07-24 |
| CL2007003005A1 (es) | 2008-05-23 |
| EP2076513A1 (fr) | 2009-07-08 |
| EA200900573A1 (ru) | 2009-10-30 |
| MA30888B1 (fr) | 2009-11-02 |
| CN101528744A (zh) | 2009-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2009000145A1 (en) | Compositions and methods for modulating c-kit and pdgfr receptors | |
| MX2010002005A (es) | Derivados de 2-heteroaril-amino-pirimidina como inhibidores de cinasa. | |
| TN2010000087A1 (en) | 5-(4- haloalkoxy) phenyl pyrimidine -2- aminecompounds and compositons as kinase inhibitors | |
| TNSN06406A1 (en) | Compounds and compositions as protein kinase inhibitors | |
| WO2005034869A3 (fr) | Composes et compositions convenant comme inhibiteurs de proteine-kinases | |
| TW200637547A (en) | Compounds and compositions as protein kinase inhibitors | |
| MX2008001969A (es) | Compuestos y composiciones como inhibidores de proteina cinasa. | |
| PL2027123T3 (pl) | Związki i kompozycje jako inhibitory kinaz białkowych | |
| WO2006124731A3 (fr) | Composes et compositions utilise(e)s en tant qu'inhibiteurs de proteines-kinases | |
| MX2009003456A (es) | Compuestos y composiciones como inhibidores de proteina cinasa. | |
| MX2008002165A (es) | Compuestos y composiciones como inhibidores de la proteina cinasa. | |
| EA200901654A1 (ru) | Ингибиторы и способы с их использованием | |
| EA201000003A1 (ru) | Ингибиторы протеинкиназ и способы их применения | |
| WO2008045627A3 (fr) | Inhibiteurs de la protéine kinase et procédés pour utiliser ceux-ci | |
| TW200726766A (en) | Compounds and compositions as protein kinase inhibitors | |
| TNSN07176A1 (en) | Compounds and compositions as protein kinase inhibitors | |
| WO2005039486A3 (fr) | Composes et compositions servant d'inhibiteurs de la proteine kinase | |
| BRPI0512422A (pt) | compostos e composições como inobidores da proteìna quinase | |
| WO2005030151A3 (fr) | Composes et compositions utiles comme inhibiteurs de la proteine kinase | |
| DOP2009000083A (es) | Composiciones y metodos para modular recpetores de pdgfr y c-kit | |
| TH98294A (th) | องค์ประกอบและวิธีการสำหรับการปรับคุม C-kit รีเซปเตอร์ | |
| TH98294B (th) | องค์ประกอบและวิธีการสำหรับการปรับคุม C-kit รีเซปเตอร์ |